A globally recognized scholar in the fields of nanoscience, inorganic chemistry, and hybrid materials, with more than 600 research publications in domestic and international journals, and holder of the core drug delivery technologies behind XAFTY® and Penetrium™.
Education
Ph.D. in Materials Engineering, Tokyo Institute of Technology (T.I.T.), Japan
Ph.D. in Inorganic Chemistry, University of Munich, Germany
B.S. / M.S. in Chemical Engineering, Yonsei University
Selected Publications
Choy JH, Kwak SY, Park JS, Jeong YJ, Portier J. Intercalative nanohybrids: a genetic molecular reservoir. Nature. 1999;402(6763):793-5.
Choy JH, Kwak SY, Jeong YJ, Park JS. Inorganic layered double hydroxides as nonviral vectors. Angewandte Chemie International Edition. 2000;39(22):4041-5.
Oh JM, Choi SJ, Lee GE, Han HJ, Choy JH. Inorganic–organic hybrid nanoparticles for fluorescence imaging and drug delivery. Chemical Society Reviews. 2012;41(18):6195-214.
Choy JH, Choi SJ, Oh JM, Park T. Clay minerals and layered double hydroxides for novel biological applications. Applied Clay Science. 2007;36(1-3):122-32.
Park M, Lee JY, Choy JH. Layered double hydroxide nanocrystals as efficient delivery carriers of genetic materials. Scientific Reports. 2016;6:19687.
“ Holder of core drug delivery technologies / Author of approximately 600 SCI-indexed papers ”
Chief Technology Officer (CTO) Gyeong-il Kim
Profile
An expert in drug delivery systems (DDS) integrating nanotechnology and organic synthesis, with a focus on advancing nanohybrid platform technologies that maximize the bioavailability of poorly soluble drugs.
Education
Ph.D. in Chemistry, Michigan State University, USA
B.S. / M.S. in Chemistry, Seoul National University
Technical Experience
Development of a manufacturing process for the anti-ulcer drug ranitidine (heterocyclic compound synthesis)
Heterocyclic compound synthesis (synthesis of Neurocrine drug candidates)
Development of manufacturing processes for chiral compounds (Samsung Fine Chemicals, Synthon, Chirad)
Development of manufacturing processes for nucleoside-based drug substance intermediates/APIs (Samchully Pharm.)
Development of drug candidates (Neurocrine, Samchully Pharm.)
Development of non-natural amino acids (AminoLogics)
Planning and development of molecular diagnostic products using PNA (Panagene)
Development of novel therapeutics for metabolic diseases, including obesity, diabetes, and fatty liver disease (Glaceum)
“ An antiviral drug development expert with experience in developing therapeutic compounds and intermediates for hepatitis C virus and HIV. ”
Chief Executive Officer (CEO) Geun-woo Jin
Profile
Leading the research and commercialization of broad-spectrum antivirals and anticancer therapeutics designed to overcome pseudo-resistance.
Education
M.S. / Ph.D. in Biochemistry, Seoul National University
B.S. in Chemistry, Seoul National University
Selected Publications
Choi, G., & Choy, J. H. (2021). Layered double hydroxide nanohybrids for biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(3), e1679.
Jin, G. W., Rejinold, N. S., & Choy, J. H. (2024). A broad-spectrum antiviral: Niclosamide–clay nanohybrid. Nature Communications, 15, 4321.
Jin, G. W., Rejinold, N. S., & Choy, J. H. (2024). Insight into preventing global dengue spread: Nanoengineered niclosamide for viral infections. Nano Letters, 24(46), 14541–14551.
Rejinold, N. S., Jin, G. W., & Choy, J. H. (2025). Harnessing nanohybridized niclosamide for precision mpox therapeutics. Advanced Healthcare Materials, 14(14), e2404818.
Jin, G. W., Rejinold, N. S., Piao, H., & Choy, J. H. (2022). A repurposing drug for COVID-19: Niclosamide-clay nanohybrid. iScience, 25(1), 103508.
“ Expert in Drug Delivery Systems / Author of 43 SCI-Indexed Papers ”
Key Researchers Hyundai Bioscience
Chief Advisor Jin-Ho Choy
Profile
A globally recognized scholar in the fields of nanoscience, inorganic chemistry, and hybrid materials, with more than 600 research publications in domestic and international journals, and holder of the core drug delivery technologies behind XAFTY® and Penetrium™.
Education
Ph.D. in Materials Engineering, Tokyo Institute of Technology (T.I.T.), Japan
Ph.D. in Inorganic Chemistry, University of Munich, Germany
B.S. / M.S. in Chemical Engineering, Yonsei University
Selected Publications
Choy JH, Kwak SY, Park JS, Jeong YJ, Portier J. Intercalative nanohybrids: a genetic molecular reservoir. Nature. 1999;402(6763):793-5.
Choy JH, Kwak SY, Jeong YJ, Park JS. Inorganic layered double hydroxides as nonviral vectors. Angewandte Chemie International Edition. 2000;39(22):4041-5.
Oh JM, Choi SJ, Lee GE, Han HJ, Choy JH. Inorganic–organic hybrid nanoparticles for fluorescence imaging and drug delivery. Chemical Society Reviews. 2012;41(18):6195-214.
Choy JH, Choi SJ, Oh JM, Park T. Clay minerals and layered double hydroxides for novel biological applications. Applied Clay Science. 2007;36(1-3):122-32.
Park M, Lee JY, Choy JH. Layered double hydroxide nanocrystals as efficient delivery carriers of genetic materials. Scientific Reports. 2016;6:19687.
“ Holder of core drug delivery technologies / Author of approximately 600 SCI-indexed papers ”
Chief Technology Officer (CTO) Gyeong-il Kim
Profile
An expert in drug delivery systems (DDS) integrating nanotechnology and organic synthesis, with a focus on advancing nanohybrid platform technologies that maximize the bioavailability of poorly soluble drugs.
Education
Ph.D. in Chemistry, Michigan State University, USA
B.S. / M.S. in Chemistry, Seoul National University
Technical Experience
Development of a manufacturing process for the anti-ulcer drug ranitidine (heterocyclic compound synthesis)
Heterocyclic compound synthesis (synthesis of Neurocrine drug candidates)
Development of manufacturing processes for chiral compounds (Samsung Fine Chemicals, Synthon, Chirad)
Development of manufacturing processes for nucleoside-based drug substance intermediates/APIs (Samchully Pharm.)
Development of drug candidates (Neurocrine, Samchully Pharm.)
Development of non-natural amino acids (AminoLogics)
Planning and development of molecular diagnostic products using PNA (Panagene)
Development of novel therapeutics for metabolic diseases, including obesity, diabetes, and fatty liver disease (Glaceum)
“ An antiviral drug development expert with experience in developing therapeutic compounds and intermediates for hepatitis C virus and HIV. ”
Chief Executive Officer (CEO) Geun-woo Jin
Profile
Leading the research and commercialization of broad-spectrum antivirals and anticancer therapeutics designed to overcome pseudo-resistance.
Education
M.S. / Ph.D. in Biochemistry, Seoul National University
B.S. in Chemistry, Seoul National University
Selected Publications
Choi, G., & Choy, J. H. (2021). Layered double hydroxide nanohybrids for biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(3), e1679.
Jin, G. W., Rejinold, N. S., & Choy, J. H. (2024). A broad-spectrum antiviral: Niclosamide–clay nanohybrid. Nature Communications, 15, 4321.
Jin, G. W., Rejinold, N. S., & Choy, J. H. (2024). Insight into preventing global dengue spread: Nanoengineered niclosamide for viral infections. Nano Letters, 24(46), 14541–14551.
Rejinold, N. S., Jin, G. W., & Choy, J. H. (2025). Harnessing nanohybridized niclosamide for precision mpox therapeutics. Advanced Healthcare Materials, 14(14), e2404818.
Jin, G. W., Rejinold, N. S., Piao, H., & Choy, J. H. (2022). A repurposing drug for COVID-19: Niclosamide-clay nanohybrid. iScience, 25(1), 103508.
“ Expert in Drug Delivery Systems / Author of 43 SCI-Indexed Papers ”
CEO geunwoo jin Email contact@hyundaibio.com Tel1544-3194 | Fax053-756-4055
